MAO A Gene and Neurotransmitter Regulation | Decoding Inflammation

By Alberto Rivera, MD · 2026-05-16 · 6 min read

The Enzyme That Sets Synaptic Tone

Monoamine oxidase A, encoded by MAO-A on the X chromosome, oxidatively deaminates serotonin, norepinephrine, and dopamine in the synaptic cleft following their release. It is the primary clearance mechanism for these neurotransmitters in the brain and peripheral nervous system. Its activity level determines, in large part, how long these molecules remain active at the receptor after release.

The MAO-A promoter contains a variable number tandem repeat (VNTR) polymorphism that determines transcriptional activity. The 3-repeat and 5-repeat alleles confer high MAO-A activity, rapid neurotransmitter degradation, lower synaptic monoamine levels. The 3.5-repeat allele confers intermediate activity. Low-activity variants degrade neurotransmitters more slowly, sustaining higher synaptic monoamine concentrations for longer after each signaling event.

The Neuroinflammatory Connection

MAO-A does not operate only in neurons. It is expressed in microglia, the brain's resident immune cells, where its activity regulates the conversion of serotonin to inflammatory metabolites via indoleamine pathways. High MAO-A activity in microglia accelerates serotonin degradation toward kynurenic acid and quinolinic acid, the latter a potent NMDA receptor agonist and neurotoxin that is elevated in neuroinflammatory states including depression, Alzheimer's disease, and Long COVID.

A 2025 study in Brain, Behavior, and Immunity demonstrated that high-activity MAO-A carriers show elevated CSF quinolinic acid levels and increased microglial activation markers relative to low-activity carriers under inflammatory challenge. The enzyme's activity determines not just neurotransmitter levels but the neuroinflammatory metabolic byproducts that accumulate when those transmitters are degraded under conditions of immune activation.

The COMT Interaction and Clinical Phenotype

MAO-A and COMT jointly govern catecholamine clearance through parallel pathways. High-activity MAO-A combined with high-activity COMT Val/Val creates a rapid clearance phenotype, low synaptic dopamine, potentially reduced prefrontal executive function and motivation. Low-activity MAO-A combined with low-activity COMT Met/Met creates a slow clearance phenotype, elevated synaptic monoamines under baseline conditions but severe accumulation under stress.

The GENEFLAMMATION framework maps MAO-A alongside COMT, MAOB, and the kynurenine pathway enzymes TDO2 and IDO1 to build a comprehensive neurotransmitter metabolism and neuroinflammatory profile, translating the genomic architecture of each patient's monoamine system into targeted therapeutic interventions.